Gilead Sciences to Present at the Punk, Ziegel & Company's Investor Symposium on Monday, November 22nd; Webcast Available Through Gilead Corporate Website

FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 19, 2004--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its corporate presentation will be webcast from the Punk, Ziegel & Company's Investor Symposium, "New Agents to Treat HIV," in New York, NY. This webcast may be accessed via the company's corporate website at www.gilead.com.

John F. Milligan, PhD, Gilead's Executive Vice President and Chief Financial Officer, will provide an overview of Gilead's HIV Franchise on Monday, November 22nd at 10:15 a.m. Eastern Time.

To access the live webcast via the internet log on to www.gilead.com. Please connect to the company's website at least 15 minutes prior to the live presentation to ensure adequate time for any software download that may be necessary to listen to the webcast.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has seven marketed products, and focuses its research and clinical programs on anti-infectives. Headquartered in Foster City, CA, Gilead has operations in North America, Europe and Australia.

For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investor Relations).
.
SOURCE: Gilead Sciences, Inc.